drugset / Trial / NCT00002532
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
Treatment
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have relapsed or refractory acute lymphocytic leukemia.
Timeline
- Start
- 1993-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intravenous |
| Subject | Daunorubicin | Small molecule | — | Intravenous |
| Subject | Dexamethasone | Small molecule | — | Intrathecal |
| Subject | Etoposide | Small molecule | — | Intravenous |
| Subject | Idarubicin | Small molecule | — | Intravenous |
| Subject | Ifosfamide | Small molecule | — | Intravenous |
| Subject | Methotrexate | Small molecule | — | Intrathecal |
| Subject | Prednisolone | Other / unclassified | — | Oral |
| Subject | Vindesine | Small molecule | — | Intravenous |
| Subject | asparaginase | Protein / enzyme biologic | — | Intravenous |
| Background | Leucovorin | Small molecule | — | — |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |